Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mario Caccese

Showing results (21-30 of 60) with videos related to

Pageof 6
Sort By:
Seminars in Oncology|January 19, 2019
Letter to Editor: Reply to R.T. Casey (Semin Oncol. 2018 Jun;45(3):151-155)Mario Caccese, Fililppo Ceccato, Matteo Fassan, et al.
Current Oncology (Toronto, Ont.)|December 24, 2025
Mitotane-Induced Hypothyroidism and Dyslipidemia in Adrenocortical Carcinoma: Sex Differences and Novel Evidence from a Thyroid Cell ModelIrene Tizianel, Arianna Beber, Alberto Madinelli, et al.
Neuro-Oncology Advances|June 7, 2024
Prolonged response to entrectinib in an adult patient with recurrent glioblastoma harboring a <i>GOPC::ROS1</i> fusionGiulia Cerretti, Marta Padovan, Angela Guerriero, et al.
Journal of Thoracic Disease|June 29, 2018
Do immune checkpoint inhibitors need new studies methodology?Roberto Ferrara, Sara Pilotto, Mario Caccese, et al.
Cancers|October 21, 2020
Clinical Management of Diffuse Low-Grade GliomasGiuseppe Lombardi, Valeria Barresi, Antonella Castellano, et al.
Journal of Endocrinological Investigation|October 9, 2024
Texture analysis can predict response to etoposide-doxorubicin-cisplatin in patients with adrenocortical carcinomaFilippo Crimì, Francesca Turatto, Carlo D'Alessandro, et al.
The Oncologist|December 4, 2023
Present and Future of Immunotherapy in Patients With Glioblastoma: Limitations and OpportunitiesMarta Maccari, Chooyoung Baek, Mario Caccese, et al.
Therapeutic Advances in Medical Oncology|June 20, 2020
Corneal side effects induced by EGFR-inhibitor antibody-drug conjugate ABT-414 in patients with recurrent glioblastoma: a prospective clinical and confocal microscopy studyRaffaele Parrozzani, Giuseppe Lombardi, Edoardo Midena, et al.
European Journal of Cancer (Oxford, England : 1990)|July 23, 2023
Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysisMarta Padovan, Marta Maccari, Alberto Bosio, et al.
Cancers|March 10, 2022
Innovating Strategies and Tailored Approaches in Neuro-OncologyAlberto Picca, David Guyon, Orazio Santo Santonocito, et al.
Pageof 6

Showing results (21-30 of 60) with videos related to

Sort By:
Pageof 6
Seminars in Oncology|January 19, 2019
Letter to Editor: Reply to R.T. Casey (Semin Oncol. 2018 Jun;45(3):151-155)Mario Caccese, Fililppo Ceccato, Matteo Fassan, et al.
Current Oncology (Toronto, Ont.)|December 24, 2025
Mitotane-Induced Hypothyroidism and Dyslipidemia in Adrenocortical Carcinoma: Sex Differences and Novel Evidence from a Thyroid Cell ModelIrene Tizianel, Arianna Beber, Alberto Madinelli, et al.
Neuro-Oncology Advances|June 7, 2024
Prolonged response to entrectinib in an adult patient with recurrent glioblastoma harboring a <i>GOPC::ROS1</i> fusionGiulia Cerretti, Marta Padovan, Angela Guerriero, et al.
Journal of Thoracic Disease|June 29, 2018
Do immune checkpoint inhibitors need new studies methodology?Roberto Ferrara, Sara Pilotto, Mario Caccese, et al.
Cancers|October 21, 2020
Clinical Management of Diffuse Low-Grade GliomasGiuseppe Lombardi, Valeria Barresi, Antonella Castellano, et al.
Journal of Endocrinological Investigation|October 9, 2024
Texture analysis can predict response to etoposide-doxorubicin-cisplatin in patients with adrenocortical carcinomaFilippo Crimì, Francesca Turatto, Carlo D'Alessandro, et al.
The Oncologist|December 4, 2023
Present and Future of Immunotherapy in Patients With Glioblastoma: Limitations and OpportunitiesMarta Maccari, Chooyoung Baek, Mario Caccese, et al.
Therapeutic Advances in Medical Oncology|June 20, 2020
Corneal side effects induced by EGFR-inhibitor antibody-drug conjugate ABT-414 in patients with recurrent glioblastoma: a prospective clinical and confocal microscopy studyRaffaele Parrozzani, Giuseppe Lombardi, Edoardo Midena, et al.
European Journal of Cancer (Oxford, England : 1990)|July 23, 2023
Actionable molecular alterations in newly diagnosed and recurrent IDH1/2 wild-type glioblastoma patients and therapeutic implications: a large mono-institutional experience using extensive next-generation sequencing analysisMarta Padovan, Marta Maccari, Alberto Bosio, et al.
Cancers|March 10, 2022
Innovating Strategies and Tailored Approaches in Neuro-OncologyAlberto Picca, David Guyon, Orazio Santo Santonocito, et al.
Pageof 6